Skip to Main Content

Paper Details

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Thorax
6
2023
Author NameAffiliation
Vincent C MarconiEmory University School of Medicine, Rollins School of Public Health
  • 1 - 1

Datasets

Release 1.2